文献速递临床试验与 GCP流行病学与生物统计

碳酸镧与碳酸钙治疗高磷血症对血液透析患者心血管事件的影响:LANDMARK随机临床试验

Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

LANDMARK开放标签随机试验纳入2374例日本透析高磷血症且合并血管钙化风险因素的患者,比较碳酸镧与碳酸钙对复合心血管事件的影响。

要点

  • 碳酸镧与碳酸钙相比未显著降低复合心血管事件风险

核心结论

  • 在血液透析高磷血症且至少合并1项血管钙化风险因素的患者中,碳酸镧相比碳酸钙未显著减少复合心血管事件。
  • 碳酸镧组心血管死亡和继发性甲状旁腺功能亢进风险较碳酸钙组升高。
  • 事件发生率低,结论可能不适用于更高风险患者。

研究设计与样本

  • 开放标签、随机、平行组临床试验,终点设盲裁定,在日本273家血液透析机构进行。
  • 纳入2374例慢性肾脏病血液透析患者,随机分为碳酸镧组(n=1154)和碳酸钙组(n=1155)。
  • 纳入标准为高磷血症且至少1项血管钙化风险因素(≥65岁、绝经后、糖尿病)。
  • 入组时间2011年11月至2014年7月,随访截至2018年6月。
  • 最终分析2309例,中位年龄69岁,女性40.5%,1851例(80.2%)完成试验。

关键数值与推荐

  • 两组均滴定至血清磷水平3.5 mg/dL至6.0 mg/dL之间。
  • 主要终点为复合心血管事件(心血管死亡、非致死性心肌梗死或卒中、不稳定心绞痛、短暂性脑缺血发作、心力衰竭或室性心律失常住院)。

临床怎么用

  • 对于血液透析高磷血症且合并血管钙化风险因素的患者,碳酸镧在降低复合心血管事件方面未优于碳酸钙。
  • 选用碳酸镧时需关注心血管死亡和继发性甲状旁腺功能亢进风险可能升高。
  • 事件率低,对更高危患者需个体化评估磷结合剂选择。

局限性

  • 开放标签设计,仅终点裁定设盲。
  • 事件发生率低,可能不足以检出差异。
  • 结论可能不适用于心血管风险更高的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Among patients with hyperphosphatemia undergoing dialysis, it is unclear whether non-calcium-based phosphate binders are more effective than calcium-based binders for reducing cardiovascular events. OBJECTIVE: To determine whether lanthanum carbonate reduces cardiovascular events compared with calcium carbonate in patients with hyperphosphatemia at risk of vascular calcification undergoing hemodialysis. DESIGN, SETTING, AND PARTICIPANTS: Open-label, randomized, parallel-group clinical trial with blinded end point adjudication performed in 2374 patients with chronic kidney disease from 273 hemodialysis facilities in Japan. Eligible patients had hyperphosphatemia and 1 or more risk factors for vascular calcification (ie, ≥65 years, postmenopausal, diabetes). Enrollment occurred from November 2011 to July 2014; follow-up ended June 2018. INTERVENTIONS: Patients were randomized to receive either lanthanum carbonate (n = 1154) or calcium carbonate (n = 1155) and titrated to achieve serum phosphate levels of between 3.5 mg/dL and 6.0 mg/dL. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite cardiovascular event (cardiovascular death, nonfatal myocardial infarction or stroke, unstable angina, transient ischemic attack, or hospitalization for heart failure or ventricular arrhythmia). Secondary outcomes included overall survival, secondary hyperparathyroidism-free survival, hip fracture-free survival, and adverse events. RESULTS: Among 2309 randomized patients (median age, 69 years; 40.5% women), 1851 (80.2%) completed the trial. After a median follow-up of 3.16 years, cardiovascular events occurred in 147 of 1063 patients in the lanthanum calcium group and 134 of 1072 patients in the calcium carbonate group (incidence rate, 4.80 vs 4.30 per 100 person-years; difference 0.50 per 100 person-years [95% CI, -0.57 to 1.56]; hazard ratio [HR], 1.11 [95%, CI, 0.88 to 1.41], P = .37). There were no significant differences in all-cause death (difference, 0.43 per 100 person-years [95% CI, -0.63 to 1.49]; HR, 1.10 [95% CI, 0.88 to 1.37]; P = .42) or hip fracture (difference, 0.10 per 100 person-years [95% CI, -0.26 to 0.47]; HR, 1.21 [95% CI, 0.62 to 2.35]; P = .58). The lanthanum carbonate group had an increased risk of cardiovascular death (difference, 0.61 per 100 person-years [95% CI, 0.02 to 1.21]; HR, 1.51 [95% CI, 1.01 to 2.27]; P = .045) and secondary hyperparathyroidism (difference, 1.34 [95% CI, 0.49 to 2.19]; HR, 1.62 [95% CI, 1.19 to 2.20]; P = .002). Adverse events occurred in 282 (25.7%) in the lanthanum carbonate group and 259 (23.4%) in the calcium carbonate groups. CONCLUSIONS AND RELEVANCE: Among patients undergoing hemodialysis with hyperphosphatemia and at least 1 vascular calcification risk factor, treatment of hyperphosphatemia with lanthanum carbonate compared with calcium carbonate did not result in a significant difference in composite cardiovascular events. However, the event rate was low, and the findings may not apply to patients at higher risk. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01578200; UMIN Clinical Trial Registry Identifier: UMIN000006815.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Ogata H, Fukagawa M, Hirakata H, et al. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial. JAMA. 2021. PMID: 34003226. doi:10.1001/jama.2021.4807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。